Literature DB >> 15986108

Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women.

Vanessa Dumeaux1, Agnès Fournier, Eiliv Lund, Françoise Clavel-Chapelon.   

Abstract

OBJECTIVE: To assess postmenopausal breast cancer risk in relation to particular patterns of oral contraceptive (OC) use according to hormone replacement therapy (HRT) exposure.
METHODS: Time-dependent Cox regression models were used to analyse information on postmenopausal women from a large-scale French cohort. Among a total of 68,670 women born between 1925 and 1950, 1405 primary invasive postmenopausal breast cancer cases were identified from 1992 to 2000.
RESULTS: A non-significant decrease in risk of around 10% was associated with ever OC use as compared to never OC use in postmenopausal women. No significant interaction was found between OC and HRT use on postmenopausal breast cancer risk. Breast cancer risk decreased significantly with increasing time since first OC use (test for trend: p=0.01); this was consistent after adjustment for duration of use or for time since last use.
CONCLUSION: No increase in breast cancer risk was associated with previous OC exposure among postmenopausal women, probably because the induction window had closed. Some women may develop breast cancer soon after exposure to OCs, leading to a deficit of cases of older women. Further investigation is therefore required to identify young women at high risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986108      PMCID: PMC1976329          DOI: 10.1007/s10552-004-8024-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  32 in total

Review 1.  Estrogen and the risk of breast cancer.

Authors:  M Clemons; P Goss
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

2.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Authors:  C Schairer; J Lubin; R Troisi; S Sturgeon; L Brinton; R Hoover
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

3.  Oral contraceptives and the risk of breast cancer.

Authors:  Polly A Marchbanks; Jill A McDonald; Hoyt G Wilson; Suzanne G Folger; Michele G Mandel; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Giske Ursin; Brian L Strom; Sandra A Norman; Phyllis A Wingo; Ronald T Burkman; Jesse A Berlin; Michael S Simon; Robert Spirtas; Linda K Weiss
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

4.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?

Authors:  Giske Ursin; Chiu-Chen Tseng; Annlia Paganini-Hill; Shelley Enger; Peggy C Wan; Silvia Formenti; Malcolm C Pike; Ronald K Ross
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.

Authors:  Merethe Kumle; Elisabete Weiderpass; Tonje Braaten; Ingemar Persson; Hans-Olov Adami; Eiliv Lund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

6.  Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.

Authors:  Agnès Fournier; Franco Berrino; Elio Riboli; Valérie Avenel; Françoise Clavel-Chapelon
Journal:  Int J Cancer       Date:  2005-04-10       Impact factor: 7.396

7.  Breast cancers among very young premenopausal women (United States).

Authors:  Michelle D Althuis; Donna D Brogan; Ralph J Coates; Janet R Daling; Marilie D Gammon; Kathleen E Malone; Janet B Schoenberg; Louise A Brinton
Journal:  Cancer Causes Control       Date:  2003-03       Impact factor: 2.506

8.  Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study.

Authors:  Vanessa Dumeaux; Elin Alsaker; Eiliv Lund
Journal:  Int J Cancer       Date:  2003-07-20       Impact factor: 7.396

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Hormonal content and potency of oral contraceptives and breast cancer risk among young women.

Authors:  M D Althuis; D R Brogan; R J Coates; J R Daling; M D Gammon; K E Malone; J B Schoenberg; L A Brinton
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  3 in total

1.  The Impact of Hormonal Contraceptives on Breast Cancer Pathology.

Authors:  Jesse A Dorchak; Sifat Maria; Joseph L Guarinoni; Anette Duensing; Stella Somiari; Jane Cavanaugh; Brenda Deyarmin; Hai Hu; Joji Iida; Craig D Shriver; Paula A Witt-Enderby
Journal:  Horm Cancer       Date:  2018-04-23       Impact factor: 3.869

2.  Associations of Oral Contraceptives with Mammographic Breast Density in Premenopausal Women.

Authors:  Lusine Yaghjyan; Carmen Smotherman; John Heine; Graham A Colditz; Bernard Rosner; Rulla M Tamimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-12-03       Impact factor: 4.090

3.  Exploring the human genome with functional maps.

Authors:  Curtis Huttenhower; Erin M Haley; Matthew A Hibbs; Vanessa Dumeaux; Daniel R Barrett; Hilary A Coller; Olga G Troyanskaya
Journal:  Genome Res       Date:  2009-02-26       Impact factor: 9.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.